The Dubai Longevity Authority, established in September 2026, positioned the emirate as a serious player in the global conversation around aging and preventive health. Abu Dhabi has been building a parallel ecosystem around precision medicine, digital health and healthy living. Together, these moves signal that longevity in the Gulf is no longer a niche interest. It’s a policy priority. Blueprint’s entry into the market is a direct commercial response to that shift.

Blueprint was founded by Johnson after his personal experiment in slowing biological aging, a protocol built around nutrition, supplementation, exercise and sleep, all tracked with obsessive precision. The brand carries that philosophy into its products. Three principles define the range: zero compromise on ingredient quality, radical transparency about what goes into each product and why, and a ‘pro-youth standard’ where nutrients are selected based on measurable outcomes.

How does it work?

Blueprint is not a single product. It’s a structured daily system that covers nutrition, supplementation and personal care. The UAE range through Valeo Health includes:

• Functional food products including extra virgin olive oil, protein bars and cocoa powder
• Supplements such as Longevity Mix, essential nutrients and antioxidants
• Skincare and haircare protocols designed to complement the nutrition and supplement stack

The brand publishes Certificates of Analysis for its products on its website, along with third-party testing reports for individual batches. That’s a level of disclosure most supplement brands avoid. For consumers who want to know exactly what they’re taking and at what dosage, it’s a meaningful differentiator. And for a market increasingly shaped by health-literate, high-income consumers across the GCC, it’s a smart commercial position.

Why does it matter?

The Gulf supplement and wellness market has grown quickly, but it has also attracted its share of overclaimed, underdocumented products. Blueprint’s approach sits at the opposite end of that spectrum. Whether or not consumers buy into the broader longevity philosophy, the transparency standards alone represent a higher bar for the category.

Ankur Majumder, co-founder of Valeo Health, framed the launch around accessibility. “With the launch of Blueprint, Valeo Health is turning that ambition into accessible, science-led solutions,” he said, “giving people across the UAE access to a globally recognised longevity approach built on transparency, structured daily protocols and evidence-based nutrition.”

Bryan Johnson also confirmed the commercial direction. “We are excited to partner with Valeo Health as our exclusive GCC partner,” he said. That exclusivity matters. It signals that Blueprint sees the GCC as a distinct, strategically important market, not just an extension of a global rollout.

The context

The UAE’s healthcare system has been shifting steadily from reactive treatment to proactive prevention. Vision 2030 in Saudi Arabia, the UAE’s own national health strategies and the broader GCC digital health push have all moved in the same direction. Consumers are catching up. Demand for wearables, health screening, personalised nutrition and longevity-focused products has grown across the region’s urban centres.

So Blueprint’s arrival is well-timed, but the real question is whether UAE consumers will engage with the structured, data-led approach the brand requires. Longevity protocols demand consistency. They work over months and years, not days. That’s a different relationship with a health product than most consumers are used to.

Still, the infrastructure is being built. The regulators are paying attention. And international brands with credible science behind them are starting to treat the Gulf as a primary market rather than an afterthought. Blueprint is available now through Valeo Health at feelvaleo.com/en-ae.

The post Blueprint lands in the UAE as longevity moves from policy to product appeared first on DH Arab.

The Abu Dhabi-based health group has launched a programme enrolling 10,000 patients, split evenly between 5,000 renal cases and 5,000 diabetes cases, to test whether continuous data from wearable devices can meaningfully improve how doctors manage both conditions. M42 Group CEO Dimitris Moulavasilis confirmed the details to Khaleej Times, describing the initiative as a move toward making continuous monitoring part of routine clinical care rather than a research novelty.

The pilot is live now. And its scale, 10,000 patients from the outset, signals that M42 is not treating this as a small proof-of-concept exercise.

How does it work?

Patients in the programme wear devices that collect health data continuously. That data is then combined with each patient’s existing clinical records, allowing the system to track changes between appointments rather than relying solely on what is captured during a scheduled visit. The goal is to give clinicians a more complete picture of how a patient’s condition is evolving day to day.

For haemodialysis patients specifically, this matters because significant physiological changes can occur between treatment sessions, with no clinical team present to observe them. Moulavasilis said the wearable data would help identify those changes and allow care to be tailored accordingly.

The pilot also builds on work M42 has already done in predictive AI. The company has developed a system that can predict vascular-access thrombosis in dialysis patients roughly a week before the complication occurs. But prediction alone is not enough. As Moulavasilis put it: “Okay, you predict, so what? You need to have the clinical care pathways to treat the people.” The wearable pilot is part of connecting those two things, continuous data feeding into predictive systems, with clinical action at the other end.

Why does it matter?

Diabetes and chronic kidney disease are among the most prevalent conditions across the GCC. The UAE and Saudi Arabia both carry significant disease burdens tied to lifestyle factors, and both governments have invested heavily in shifting health systems toward prevention and early intervention. A model that catches deterioration before it becomes a crisis fits directly into that agenda.

But the pilot is also about something broader than wearables. It reflects a shift in how Abu Dhabi is thinking about health data infrastructure. The emirate’s Malaffi health information exchange, the Abu Dhabi Biobank (which opened in April with capacity for up to five million biological samples), and investments in genomics and environmental science are being built to work together. Moulavasilis described an ecosystem where biological samples, genomic data, lifestyle information, and real-world patient-generated data can be linked and used in combination.

That kind of infrastructure is relevant not just to patient care but to life-sciences investment. The ability to link wearable data with biobank samples and genomic profiles could make Abu Dhabi attractive to biotechnology and pharmaceutical companies looking for research environments with rich, connected datasets.

The context

Abu Dhabi has been methodical in building the components of a precision health system over the past several years. The Biobank, the Malaffi system, liquid biopsy programmes for cancer detection, gene-editing collaborations with Mammoth Biosciences, and pharmacogenomics applications have each added a layer to that infrastructure. The M42 wearable pilot is another layer.

Dr Asma Al Mannaei, Executive Director of Life Sciences at the Department of Health, Abu Dhabi, has stressed the importance of moving innovation out of the research stage and into actual healthcare delivery. That pressure to translate rather than just develop is visible in the structure of this pilot: real patients, real devices, real clinical integration from day one.

For health systems across the GCC watching Abu Dhabi’s approach, the key question is whether continuous monitoring at scale can change outcomes, not just collect data. The answer, when it comes from 10,000 patients, will carry weight.

The post M42 launches 10,000-patient wearable pilot in Abu Dhabi to reshape chronic disease care appeared first on DH Arab.

The company entered international markets earlier this year with a clinical programme in Santiago, Chile. Dubai is its second international market, and the UAE’s combination of medical infrastructure, health-conscious policy environment, and patient population makes it a logical next step. Indoma’s focus covers stroke recovery, mild traumatic brain injury, Parkinson’s Disease, Multiple Sclerosis, and other neurological conditions.

Oren Schneider, Co-founder and Chief Executive Officer of Indoma, was direct about the founding logic. “Hospital discharge is a milestone, not the end of the rehabilitation journey,” he said. “We built Indoma to give patients and families a clear path forward when the next step is uncertain.” The company name draws on the word ‘indomitable’, a deliberate signal of the clinical philosophy behind it.

How does it work?

Following a physician-led assessment, Indoma builds a personalised care plan for each patient. That plan brings together medical oversight, a multidisciplinary rehabilitation team, and dedicated care coordination. The emphasis is on high-frequency, high-intensity, repetitive therapy delivered consistently over time — the conditions that neuroplasticity science identifies as necessary for meaningful recovery gains.

The company selects and deploys specific rehabilitation technologies chosen to support each patient’s neurological profile. Care is provided at home, not in a clinic. So the environment is familiar, the schedule is organised around the patient’s life, and progress is monitored on an ongoing basis by the clinical team.

• Physician-led intake assessment and personalised treatment planning
• Multidisciplinary rehabilitation across physical, cognitive, and neuromuscular function
• Technology-augmented therapy sessions delivered in the patient’s home
• Dedicated care coordination and continuous clinical review
• Referral-based integration with the patient’s existing medical team

Why does it matter?

Post-acute neurological rehabilitation has long been one of healthcare’s most underdeveloped areas. Patients who do not qualify for inpatient rehabilitation, or who have been discharged after reaching what clinicians call a ‘plateau’, often receive little structured support. But the science behind neuroplasticity, the brain’s capacity to adapt and relearn after injury, challenges the assumption that recovery has a fixed endpoint.

Dr. Teo Forcht Dagi, Neurosurgeon and Chairman and Chief Medical Officer of Indoma, put it clearly: “The brain’s capacity to recover is not fixed, but can be activated and enhanced by high-frequency, high-intensity, repetitive input and consistent delivery.” In the UAE, Dr. Dagi said Indoma intends to work as colleagues to existing neurologists, neurosurgeons, and rehabilitation physicians, and to meet the clinical governance standards expected of any academic centre. Dr. Dagi holds an appointment as Professor of Neurosurgery at the Mayo Clinic College of Medicine and Science.

Leading clinical delivery in Dubai is Dr. Nazakat Hussain, Indoma’s UAE Medical Director. He is a locally based Consultant in Physical Medicine and Rehabilitation with over 30 years of experience across the UK and UAE, and also serves as Director of the Spinal Cord Injury Program and Clinical Lead for Neurorehabilitation at the Specialized Rehabilitation Hospital in Abu Dhabi.

The context

The UAE has invested heavily in building a healthcare system capable of handling complex, chronic, and neurological conditions. That investment is visible in Abu Dhabi’s specialist rehabilitation infrastructure and in Dubai’s growing network of tertiary care providers. Indoma’s model is designed to complement, not compete with, that ecosystem. The company says it will build referral relationships with hospitals, physicians, and rehabilitation partners, working alongside the medical teams patients already know.

And the timing is relevant. Neurological conditions are among the fastest-growing contributors to disability-adjusted life years across the GCC, driven by an ageing population, rising rates of cardiovascular disease, and road traffic incidents. A model that extends recovery support into the home, and holds itself to academic clinical standards, fits the direction that Gulf health systems are heading. Indoma will begin accepting patients through referral or direct inquiry in the coming weeks.

The post US neurorehabilitation firm Indoma opens in Dubai, bringing home-based brain recovery care to the UAE appeared first on DH Arab.

The move is practical in its design but significant in what it signals. For the first time, a user seeking emotional support through Takalam can, within the same digital journey, access laboratory or diagnostic services without switching platforms, calling a clinic, or navigating an entirely separate system.

The announcement was timed to World Mental Health Day. And while that timing has obvious symbolic value, the substance behind it is what matters most. Both organisations are anchored in Abu Dhabi’s Hub71 tech ecosystem, specifically through Hub71+ Life Sciences, which connects HealthTech startups with established health sector partners. That relationship gave Unilabs Middle East early access to Takalam as a startup within the ecosystem, and this expanded collaboration is a direct result of that engagement.

How does it work?

Through the Takalam app, users can now explore and book selected Unilabs Middle East diagnostic health packages. The integration creates a single digital touchpoint for two services that are usually accessed through completely different channels. Key features of the collaboration include:

• In-app access to Unilabs Middle East health packages for Takalam users
• A connected booking journey without leaving the Takalam platform
• Combined access to mental wellbeing support and physical health diagnostics
• Grounding in Hub71+ Life Sciences, supporting startup-to-anchor market collaboration

Takalam itself offers a mix of AI-powered wellbeing support through its tool Aila, access to vetted counsellors, and group support programmes. Adding diagnostics to that mix is, as Takalam’s CEO Khawla Hammad put it, a natural extension of the platform’s mission to make proactive, personalised wellbeing a normal part of everyday life in the Arab world.

Why does it matter?

The UAE has invested heavily in digital health infrastructure over the past several years, and initiatives like this reflect where that investment is heading. Rather than building new standalone platforms, the more interesting work now is connecting existing ones. That’s a harder problem to solve, and it’s where real clinical value tends to emerge.

There is also a mental health dimension worth taking seriously. Stigma around mental health remains a barrier to help-seeking across much of the Arab world. Embedding diagnostic access within a mental health platform, rather than the other way around, sends a quiet but important message: emotional wellbeing is a legitimate entry point into the broader health system.

Dr Ali Bayoumi, Medical Officer at Unilabs Middle East, pointed to a clear shift in the region toward preventive and proactive healthcare. People are not just seeking treatment anymore. They want to understand their health before something goes wrong. That demand is what makes this kind of partnership commercially viable, not just clinically sensible.

The context

This partnership sits squarely within the UAE’s wider health agenda. The country’s leadership has consistently pushed for a move away from reactive, hospital-centric care toward prevention, early intervention, and digital-first access. Saudi Arabia’s Vision 2030 carries a parallel commitment, with preventive health forming a core pillar of its health transformation programme.

Across the GCC, the challenge has been translating those policy ambitions into products that people actually use. Takalam, founded in Abu Dhabi in 2021 and backed by Hub71, is one of the clearer examples of a regional platform built specifically for Arab users, in Arabic, with cultural context built into its design. Unilabs Middle East brings clinical credibility and scale, with the broader Unilabs network spanning more than 11,500 specialists across 12 countries.

So the combination here is not accidental. It’s a model worth watching, and one that other GCC health platforms will likely consider replicating.

The post Unilabs Middle East and Takalam link diagnostics to mental health in one app appeared first on DH Arab.

The group launches with an existing asset, Trellis Hospital in Umm Suqeim, a JCI-accredited, 50-bed facility offering more than 35 specialties including cardiology, obstetrics, paediatrics and orthopaedics. Two clinics in Expo City and Jumeirah Village Circle are set to open by end of 2026, with a further hospital and two more clinics planned as the network grows.

How does it work?

Trellis Health organises its care model around four commitments to patients:

• One coordinated team across the care journey
• Clinicians who prioritise patient outcomes over throughput
• A simplified patient experience with technology built in
• Long-term follow-through beyond the initial episode of care

The technology layer is not incidental. Smart tools are positioned as a way to make access easier, not just to digitise existing processes.

Why does it matter?

Dubai’s population is projected to reach 5.8 million by 2040 under the Dubai Urban Master Plan, with 25 percent more land allocated to health and education. That is a significant supply gap, and private capital is going to fill most of it. Al Ghurair entering the sector, with the balance sheet and community presence to build at scale, signals that major family conglomerates see healthcare as the next long-term infrastructure play in the UAE.

The context

This launch fits a broader pattern across the GCC, where governments are actively encouraging private sector participation in healthcare to reduce pressure on public systems and meet rising demand from growing, aging populations. In Saudi Arabia, Vision 2030 has made this explicit. The UAE has its own parallel push, with Dubai and Abu Dhabi both attracting significant investment in private hospital networks. Trellis Health is not the first to move, but Al Ghurair’s name and capital give it a credible foundation to build something that lasts. For more information, visit trellishospital.com.

The post Al Ghurair enters healthcare with Trellis Health launch in Dubai appeared first on DH Arab.

The launch is supported by a dedicated out-of-home and digital campaign running across the GCC, targeting the growing base of health-conscious consumers, athletes, and professionals who have made the Gulf one of the most active markets for wearables globally. WHOOP has not disclosed exact subscriber numbers for the region, but the investment behind this rollout suggests the company sees serious commercial opportunity here.

How does it work?

WHOOP is a screenless wearable worn on the wrist that continuously tracks physiological data around the clock. There is no display on the device itself. All insights are delivered through the app, which means the quality of that app experience is central to what the product actually is. The newly redesigned Arabic app gives users access to the platform’s core metrics:

• Recovery scores based on heart rate variability, resting heart rate, and sleep performance
• Strain tracking that measures cardiovascular load across activity and daily life
• Sleep coaching with detailed breakdowns of sleep stages and consistency
• Health monitoring features including blood oxygen and skin temperature
• AI-powered insights through WHOOP Coach, now available in Arabic

The interface is fully right-to-left, with Arabic-language coaching cues and personalised recommendations built into the daily experience. This is not a translated overlay. The company says it is a redesigned product layer built for Arabic speakers specifically.

Why does it matter?

The GCC is not a peripheral market for health technology. Saudi Arabia’s Vision 2030 has placed preventive health and physical wellness at the centre of national strategy. The UAE has its own ambitious targets around longevity and digital health infrastructure. Across the Gulf, governments are actively pushing citizens toward healthier lifestyles, and consumer spending on health and fitness continues to rise sharply year on year.

But the dominant wearable platforms have historically delivered their most sophisticated features in English first, with Arabic support lagging behind or missing entirely. That gap has real consequences. When insights, coaching, and data are communicated in a second language, users engage less, trust the data less, and are less likely to act on recommendations. WHOOP’s decision to invest in a purpose-built Arabic experience addresses something that has quietly frustrated Arabic-speaking users of health platforms for years.

So for regional health professionals and policymakers, this matters beyond brand competition. Better-localised tools mean better engagement with preventive health behaviours, which is precisely what GCC governments are trying to encourage.

The context

WHOOP has been expanding aggressively beyond its original base of elite athletes and sports teams. The platform now positions itself as a tool for anyone serious about understanding their body, from executives managing stress and sleep to everyday fitness enthusiasts tracking their training load. The Arabic launch fits that broader strategy while also responding to competitive pressure, with Apple Watch, Garmin, and Samsung’s Galaxy Watch all investing in regional Arabic capabilities in recent years.

What makes this moment notable is the combination of product investment and marketing commitment. An out-of-home campaign across multiple GCC markets is not cheap, and it signals that WHOOP is treating the Arabic-speaking world as a primary market rather than an expansion footnote. Whether the company can convert that visibility into sustained regional growth will depend on pricing accessibility and local partnerships, areas where details remain limited for now. Still, the direction is clear.

The post WHOOP goes Arabic: the wearable brand targets GCC health-conscious consumers with full language overhaul appeared first on DH Arab.

The startup was founded by Abdullatif Al-Baroudi and Albaraa Abdulsalam. It connects patients with licensed healthcare professionals who deliver services at home, covering medical consultations, nursing, physiotherapy, elderly care, laboratory testing and diagnostic imaging. It currently operates in Aleppo, Damascus and Hama.

Before raising external capital, the founders funded operations independently, built a minimum viable product and tested the model directly with patients and medical professionals. They also went through the ScaleUp 2025 programme and received mentorship through ChangeMakers, run by Maynger Ventures, and Thimar, an initiative focused on helping Syrian startups prepare for investment.

The money will be used for…

• Transitioning from the MVP to a fully developed mobile application, set for public launch in November 2026
• Strengthening the technology infrastructure underpinning the platform
• Expanding the network of licensed healthcare providers on the platform
• Growing the team ahead of entry into new Syrian markets

Why does it matter?

Access to healthcare outside hospitals remains a serious gap in Syria. Alo Hakeem is trying to fill that gap with a structured, tech-enabled model rather than informal referral networks. It’s a modest raise, but in a market where external investment is rare, $165,000 in pre-seed capital carries real weight. The company’s plan to enter four additional governorates by end of 2027 suggests the founders are thinking about national reach, not just city-level validation.

The context

EBLA Ventures focuses specifically on Syrian entrepreneurs, which makes this round more than a financial transaction. It signals a small but growing ecosystem of investors willing to back founders operating in conflict-affected or post-conflict markets. Across the broader Arab world, home healthcare has attracted serious capital, including in Saudi Arabia and the UAE, where Vision 2030 and national health strategies have pushed demand for out-of-hospital care. Syria is years behind those markets structurally, but the underlying demand is real. Alo Hakeem is making an early bet that the infrastructure to serve it can be built now.

The post Syrian healthtech Alo Hakeem raises $165,000 pre-seed to bring home healthcare to scale appeared first on DH Arab.

The programme invites patients at Cleveland Clinic Abu Dhabi’s oncology centre to voluntarily donate biological samples at various points during their care. Those samples, paired with relevant clinical data, are then stored and made available to researchers working on cancer biology, early detection, and targeted therapies. The scope is broad by design. By capturing samples across different cancer types, treatment stages, and patient profiles, the biobank aims to build a dataset that reflects the genuine diversity of the UAE’s population.

How will it work?

Patients who consent to participate provide blood samples and, where clinically appropriate, tumour tissue. These are collected alongside de-identified health information covering diagnosis, treatment history, and outcomes. Researchers, both within Cleveland Clinic Abu Dhabi and through external collaborations, can then apply to access the repository for approved studies. The Abu Dhabi Biobank, which already manages one of the region’s more established population health databases, provides the storage infrastructure and governance framework. That existing backbone matters. It means the cancer initiative isn’t starting from scratch on data management or ethics protocols.

• Voluntary patient participation with informed consent at each stage
• Collection of blood and tumour tissue samples across cancer types
• Integration with de-identified clinical data for research use
• Governed under Abu Dhabi Biobank’s existing data framework
• Open to collaborative research from local and international institutions

Why does it matter?

Personalised oncology, the idea that treatment should be matched to the molecular profile of a patient’s specific cancer rather than a population average, is one of the most active areas in global medicine. But it depends on data. Large, well-annotated sample collections are what allow researchers to identify genetic markers, test drug responses across subgroups, and build the predictive models that make precision treatment possible. The Arab world has historically been underrepresented in global biobanks, which skews research findings and limits how well international treatment protocols translate to regional patients. A UAE-based cancer biobank addresses that gap directly. The samples collected here will reflect genetic backgrounds, lifestyle factors, and disease presentations specific to this population.

The context

This initiative fits squarely within Abu Dhabi’s broader push to position itself as a life sciences hub. The emirate’s health strategy has placed increasing emphasis on research capacity, data infrastructure, and reducing long-term dependence on imported medical knowledge. Abu Dhabi Biobank itself was established as part of that framework, and its partnership with Cleveland Clinic Abu Dhabi, one of the region’s most prominent tertiary care providers, gives the cancer programme immediate clinical credibility and patient access. So the timing is not accidental. Across the GCC, governments are investing in the kind of foundational health data infrastructure that makes locally relevant research possible. This biobank is a concrete example of that investment taking shape in a clinical setting, with direct implications for how cancer care in the region might look a decade from now.

The post Cleveland Clinic Abu Dhabi launches cancer biobank to drive personalised treatment research appeared first on DH Arab.

FAP causes hundreds, sometimes thousands, of polyps to form throughout the colon. Left untreated, the progression to cancer is not a risk so much as a near-certainty. For the patient in question, waiting was not a viable option. The surgical team at Cleveland Clinic Abu Dhabi chose a total proctocolectomy with ileal pouch-anal anastomosis, commonly called a J-pouch procedure. In plain terms, this means removing the entire colon and rectum, then constructing an internal reservoir from the small intestine that allows the patient to maintain normal bowel function without a permanent stoma.

How did it work?

The operation was carried out entirely using robotic technology, with no open incisions beyond small ports for the robotic arms. The surgical team worked through multiple abdominal quadrants, a level of complexity that typically demands exceptional coordination and instrument control. Robotic systems offer magnified three-dimensional visualization and a range of motion that exceeds what human hands can achieve in confined spaces, which matters enormously when operating near critical pelvic structures.

The J-pouch itself requires meticulous construction. The ileum, the final section of the small intestine, is folded and joined to form a pouch that mimics the storage function of the rectum. Connecting this internally, while preserving the surrounding nerves and muscles, is where the procedure becomes genuinely difficult. The team completed this without converting to open surgery, and the patient recovered without major complications.

Why does it matter?

This case matters for a few reasons. First, it confirms that highly specialized preventive cancer surgery is now available locally, without patients needing to travel abroad for complex oncological or hereditary procedures. That has real consequences for families across the UAE and the broader GCC who carry inherited cancer syndromes and may not know where to seek care.

But there is also a wider signal here. Preventive intervention, identifying and treating cancer risk before a diagnosis occurs, is central to what Saudi Vision 2030 and the UAE’s National Strategy for Wellbeing are trying to accomplish. Keeping people healthy rather than treating them once they are already ill is both better medicine and better economics.

The context

The UAE has invested heavily in building domestic tertiary care capability, and cases like this one reflect that progress concretely. Cleveland Clinic Abu Dhabi, established under the Abu Dhabi government’s push to develop world-class healthcare within the emirate, has steadily expanded its surgical subspecialties since opening in 2015.

Robotic surgery adoption across the GCC has accelerated over the past five years, with hospitals in Saudi Arabia, Qatar, and the UAE all expanding their programs. Still, fully robotic procedures for hereditary colorectal conditions remain relatively rare anywhere in the world. Completing one successfully, locally, on a young patient with a near-certain cancer trajectory, is the kind of outcome that reinforces confidence in regional surgical capability and, more practically, may encourage other high-risk patients to seek genetic counseling and timely care before cancer takes hold.

The post Cleveland Clinic Abu Dhabi completes fully robotic preventive colorectal surgery on high-risk patient appeared first on DH Arab.

Ultrahuman is a global health technology company best known for its continuous glucose monitoring tools and wearable ring device. The company already collects granular biometric data across large user populations. Pairing that capability with ADPHC’s public health infrastructure and clinical reach gives this project real weight. This is not a pilot app or a wellness experiment. Both parties are committing to clinical validation, which means the model will need to prove it works before it gets deployed at scale.

How will it work?

The Biological Health Age model will pull together multiple data streams to produce a single, interpretable score that reflects a person’s physiological condition. According to the agreement, the model will combine:

• Clinical biomarkers from blood and metabolic testing
• Continuous biometric data collected via wearable devices
• Lifestyle and behavioural inputs tracked over time
• Population-level health data from Abu Dhabi’s existing public health records

The clinical validation process will be conducted in Abu Dhabi, which means the model will be tested and refined against a real Gulf population, not adapted from data collected elsewhere. That distinction matters more than it might seem.

Why does it matter?

Most preventive health tools available today were built on Western population datasets. Genetic variation, dietary patterns, metabolic profiles, and disease prevalence differ significantly across ethnic groups. A Biological Health Age model trained and validated on Abu Dhabi’s diverse, multicultural population could produce far more accurate results for people across the GCC than anything currently on the market.

But the practical stakes go beyond accuracy. If a clinician can tell a 42-year-old patient that their biological age is 51, that information changes the conversation. It creates urgency. It makes abstract risk visible. And it gives individuals something concrete to work toward reducing. That is the kind of tool that can shift population health behaviour at scale, which is exactly what Abu Dhabi’s long-term health strategy requires.

The context

This partnership fits directly into Abu Dhabi’s broader agenda on preventive care and data-driven health. The emirate has spent years building the infrastructure for this kind of initiative, from population health registries to digital patient records to national screening programmes. ADPHC has been central to that work.

Across the UAE and wider GCC, governments are under pressure to reduce the burden of non-communicable diseases, including diabetes, cardiovascular disease, and obesity, all of which are closely linked to accelerated biological ageing. Saudi Arabia’s Vision 2030 has made similar commitments to preventive health and health data investment. So this Abu Dhabi initiative is arriving at a moment when regional appetite for this kind of science is high. The question now is whether the clinical validation delivers results that hold up.

The post Abu Dhabi bets on biological age tech to reshape preventive health appeared first on DH Arab.